{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NaCl-saline+placebo&page=50", "query": { "intervention": "NaCl-saline placebo", "page": 50 }, "page_size": 10 }, "pagination": { "page": 50, "page_size": 10, "total_count": 1336, "total_pages": 134, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NaCl-saline+placebo&page=51&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NaCl-saline+placebo&page=49&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T18:41:03.140Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07482423", "title": "XVIE to Treat Androgenetic Alopecia (AGA)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Androgenetic Alopecia" ], "interventions": [ { "name": "Decellularized allogeneic human amniotic fluid", "type": "BIOLOGICAL" }, { "name": "Sodium chloride 0.9% injectable solution", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Restore Biologics Holdings, Inc. dba Xtressé", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2026-12-01", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-21T18:41:03.140Z", "location_count": 2, "location_summary": "Orlando, Florida • Marriottsville, Maryland", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Marriottsville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07482423" }, { "nct_id": "NCT01410227", "title": "Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Von Willebrand Disease" ], "interventions": [ { "name": "Recombinant von Willebrand factor (rVWF)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Recombinant factor VIIII (rFVIII)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 49, "start_date": "2011-11-01", "completion_date": "2014-02-01", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-21T18:41:03.140Z", "location_count": 10, "location_summary": "Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01410227" }, { "nct_id": "NCT02462161", "title": "Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease", "Mild Cognitive Impairment" ], "interventions": [ { "name": "Insulin aspart", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 24, "start_date": "2015-03-20", "completion_date": "2019-04-16", "has_results": false, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-10-21T18:41:03.140Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02462161" }, { "nct_id": "NCT03988842", "title": "Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Embolism With Acute Cor Pulmonale", "Pulmonary Embolism", "Pulmonary Embolism With Pulmonary Infarction", "Pulmonary Embolism Subacute Massive", "Right Ventricular Dysfunction", "Right Ventricular Failure" ], "interventions": [ { "name": "Alteplase", "type": "DRUG" }, { "name": "Unfractionated heparin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Victor Tapson, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 4, "start_date": "2019-07-25", "completion_date": "2020-04-05", "has_results": true, "last_update_posted_date": "2021-06-11", "last_synced_at": "2026-10-21T18:41:03.140Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03988842" }, { "nct_id": "NCT02178800", "title": "Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK1265744 Tablets", "type": "DRUG" }, { "name": "Injectable GSK1265744", "type": "DRUG" }, { "name": "Placebo for GSK1265744 Tablets", "type": "DRUG" }, { "name": "Injectable Placebo for GSK1265744", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 199, "start_date": "2015-02", "completion_date": "2018-07-13", "has_results": true, "last_update_posted_date": "2021-10-18", "last_synced_at": "2026-10-21T18:41:03.140Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02178800" }, { "nct_id": "NCT05743881", "title": "A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus", "Human Metapneumovirus" ], "interventions": [ { "name": "mRNA-1345", "type": "BIOLOGICAL" }, { "name": "mRNA-1365", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Nimenrix", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Months", "maximum_age": "24 Months", "sex": "ALL", "summary": "5 Months to 24 Months" }, "enrollment_count": 186, "start_date": "2023-02-15", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-21T18:41:03.140Z", "location_count": 12, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Melrose Park", "state": "Illinois" }, { "city": "Lafayette", "state": "Louisiana" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743881" }, { "nct_id": "NCT03107377", "title": "Phase 2B/3 Double-blinded Placebo-controlled", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Chlamydia Trachomatis Infection" ], "interventions": [ { "name": "EVO100", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Evofem Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 860, "start_date": "2017-11-03", "completion_date": "2019-08-22", "has_results": true, "last_update_posted_date": "2020-08-12", "last_synced_at": "2026-10-21T18:41:03.140Z", "location_count": 50, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03107377" }, { "nct_id": "NCT02421367", "title": "Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Dengue" ], "interventions": [ { "name": "TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "20 Years to 49 Years" }, "enrollment_count": 140, "start_date": "2015-08", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2019-09-25", "last_synced_at": "2026-10-21T18:41:03.140Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Silver Spring, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02421367" }, { "nct_id": "NCT06005441", "title": "A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Subcutaneous Fat" ], "interventions": [ { "name": "CBL-514 injection", "type": "DRUG" }, { "name": "CBL-A1 Injection", "type": "DRUG" }, { "name": "CBL-A2 Injection", "type": "DRUG" }, { "name": "0.9% Sodium Chloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Caliway Biopharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 173, "start_date": "2023-11-10", "completion_date": "2024-10-18", "has_results": false, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-10-21T18:41:03.140Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06005441" }, { "nct_id": "NCT04634253", "title": "A Study of LY3462817 in Participants With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "LY3462817", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2021-01-04", "completion_date": "2022-06-29", "has_results": true, "last_update_posted_date": "2023-07-12", "last_synced_at": "2026-10-21T18:41:03.140Z", "location_count": 7, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Palm Desert, California + 4 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634253" } ] }